news

Oct 10, 2024
Oct 8, 2024
Oct 2, 2024
Linkedin-in

Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study

Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study

Met standard bioequivalence (BE) criteria Cmax, AUC0-t, and AUC0-∞ Ctrough criterion was met LPCN 1154 was well tolerated with no sedation or somnolence events observed On track for NDA filing

Recent

Press

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

Read More

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries

Read More

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

Read More

Focus on enhancing health

We are pioneers of developing innovative drug products targeting significant unmet medical needs.